{
    "pmcid": "10536364",
    "qa_pairs": {
        "How can insights from SARS-CoV-2 nanobody development be applied to African Swine Fever (ASF) research?": [
            "By targeting viral proteins critical for ASFV entry and replication",
            "By increasing the mutation rate of ASFV",
            "By reducing the immune response in pigs",
            "By enhancing ASFV transmission between pigs"
        ],
        "What advantage do nanobodies have over conventional antibodies according to the paper?": [
            "Smaller size, higher stability, and ease of production",
            "Larger size and increased complexity",
            "Lower stability and more difficult production",
            "Higher cost and longer development time"
        ],
        "What is the primary target for neutralizing antibodies and nanobodies in the SARS-CoV-2 spike protein?": [
            "The receptor-binding domain (RBD)",
            "The N-terminal domain (NTD)",
            "The S2 subunit",
            "The fusion peptide"
        ],
        "What therapeutic application is mentioned for nanobodies targeting the SARS-CoV-2 spike protein?": [
            "Blocking viral entry into host cells",
            "Enhancing viral replication",
            "Increasing viral mutation rates",
            "Facilitating viral assembly"
        ],
        "Why is cross-reactivity important in the design of nanobodies for SARS-CoV-2?": [
            "To ensure efficacy against multiple variants",
            "To increase the size of the nanobodies",
            "To reduce the production cost",
            "To limit the binding to a single variant"
        ]
    }
}